Association between cardiovascular-kidney-metabolic syndrome, inflammatory biomarkers, and cardiovascular outcomes: Insights from the MESA study
Muhammad Imtiaz Ahmad(Wake Forest University), Michael D. Shapiro(Wake Forest University), Roger S. Blumenthal(House of Representatives), Neha J. Pagidipati(Duke University), Parag Anilkumar Chevli(Wake Forest University), Garima Sharma(Inova Fairfax Hospital), Khurram Nasir(Houston Methodist), Joao Lima(Johns Hopkins University), Michael J. Blaha(University of California San Diego), Jared Spitz(Johns Hopkins Hospital), Saeid Mirzai
Cited by 5
Related Papers
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
|Journal of the American College of Cardiology|2018|2.6k
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2017|2.1k
Interpretation of the evidence for the efficacy and safety of statin therapy
|The Lancet|2016|1.8k
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe
|European Heart Journal|2021|1.7k